CD4 and neoplasm: These observations were consistent with the observed pharmacology efficacy and our MOA hypothesis per above studies: CD4+-TILs (Treg) plays key role in suppression of anti-tumor immunity (CD8+ CTLs) in MC38 tumors and CD4+-TILs (Teff) plays key role in anti-tumor immunity in Hepa1-6 tumors.